Email newsletter pointed out that there's a page for tips and materials for fundraising on the ME/CFS Research Foundation website: https://mecfs-research.org/en/support/fundraiser/
Last edited:
OrganicChilli
Senior Member (Voting Rights)
Website Feedback
Wir überarbeiten aktuell unsere Webseite und Content-Strategie – und dafür brauchen wir dein Feedback! Deine Antworten helfen uns, Inhalte klarer, relevanter und hilfreicher zu gestalten. Die Umfrage dauert nur wenige Minuten – danke fürs Mitmachen!
form.typeform.com
Chandelier
Senior Member (Voting Rights)
Slightly off-topic but there’s also the Austrian WE&ME Foundation backed by the Ströck family.
Several of their sons suffer from ME/CFS and at least one of them is quite active on X.
They are doing lots of awesome stuff and maybe someone could reach out to invite him over to S4ME?
Edit: I found his account:
Nitter link for anyone without X.
X link
Last edited:
OrganicChilli
Senior Member (Voting Rights)
Also a reminder that we have a thread for the German translation: https://www.s4me.info/threads/translating-s4me-fact-sheets-into-german.45331/
OrganicChilli
Senior Member (Voting Rights)
Update: research funding strategy of the ME/CFS Research Foundation
In 2026, our research funding will support projects that, based on the latest scientific findings, address the following aspects:
Elucidation of the disease mechanisms, underlying central ME/CFS symptoms, such as PEM (post-exertional malaise), pain, muscle weakness, cognitive dysfunction, circulatory disorders, sleep disorders and dysautonomia.
Developing reliable diagnostic, prognostic or predictive (taking into account important variables such as sex/gender, age, duration of illness and severity). We focus on projects investigating autoimmunity, immune dysregulation, metabolic disorders, inflammation, vascular dysfunction, and nervous system dysfunction as causal factors in the development and progression of ME/CFS.
Testing innovative, disease-mechanism-targeted drugs and treatment approaches for their suitability for effective and safe treatment of ME/CFS. This includes drugs already approved for other diseases, such as CD19+ or CD20+ B-cell depletion, CD38+ plasmablast/cell depletion, B-cell receptor signalling and granulocyte inhibition, selective B/T-cell depletion, inhibition of plasma cell maturation and GLP-1 receptor agonists, or other promising drug candidates targeting the above-mentioned disease mechanisms.
In 2026, our research funding will support projects that, based on the latest scientific findings, address the following aspects:
Elucidation of the disease mechanisms, underlying central ME/CFS symptoms, such as PEM (post-exertional malaise), pain, muscle weakness, cognitive dysfunction, circulatory disorders, sleep disorders and dysautonomia.
Developing reliable diagnostic, prognostic or predictive (taking into account important variables such as sex/gender, age, duration of illness and severity). We focus on projects investigating autoimmunity, immune dysregulation, metabolic disorders, inflammation, vascular dysfunction, and nervous system dysfunction as causal factors in the development and progression of ME/CFS.
Testing innovative, disease-mechanism-targeted drugs and treatment approaches for their suitability for effective and safe treatment of ME/CFS. This includes drugs already approved for other diseases, such as CD19+ or CD20+ B-cell depletion, CD38+ plasmablast/cell depletion, B-cell receptor signalling and granulocyte inhibition, selective B/T-cell depletion, inhibition of plasma cell maturation and GLP-1 receptor agonists, or other promising drug candidates targeting the above-mentioned disease mechanisms.